Review



phn human research tissue  (Teva)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Teva phn human research tissue
    Keratinocyte biomarker immunolabeling examples demonstrate the discreet variability among individual patients of the innervation pathology-matched <t>PHN</t> cohort. For every biomarker (A–I), at least one individual patient within the total cohort had significantly less ipsilateral labeling than contralateral (top plates), and at least one individual patient within the total cohort also had significantly more ipsilateral labeling than contralateral (bottom plates). A few TrpV1-positive small fiber IENF are also seen (G, white arrows). Mag bar = 50 µm for all images. IENF, intraepidermal nerve fibers; PHN, postherpetic neuralgia; TrpV1, transient receptor potential vanilloid 1.
    Phn Human Research Tissue, supplied by Teva, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phn human research tissue/product/Teva
    Average 90 stars, based on 1 article reviews
    phn human research tissue - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Cutaneous targets for topical pain medications in patients with neuropathic pain: individual differential expression of biomarkers supports the need for personalized medicine"

    Article Title: Cutaneous targets for topical pain medications in patients with neuropathic pain: individual differential expression of biomarkers supports the need for personalized medicine

    Journal: Pain Reports

    doi: 10.1097/PR9.0000000000001121

    Keratinocyte biomarker immunolabeling examples demonstrate the discreet variability among individual patients of the innervation pathology-matched PHN cohort. For every biomarker (A–I), at least one individual patient within the total cohort had significantly less ipsilateral labeling than contralateral (top plates), and at least one individual patient within the total cohort also had significantly more ipsilateral labeling than contralateral (bottom plates). A few TrpV1-positive small fiber IENF are also seen (G, white arrows). Mag bar = 50 µm for all images. IENF, intraepidermal nerve fibers; PHN, postherpetic neuralgia; TrpV1, transient receptor potential vanilloid 1.
    Figure Legend Snippet: Keratinocyte biomarker immunolabeling examples demonstrate the discreet variability among individual patients of the innervation pathology-matched PHN cohort. For every biomarker (A–I), at least one individual patient within the total cohort had significantly less ipsilateral labeling than contralateral (top plates), and at least one individual patient within the total cohort also had significantly more ipsilateral labeling than contralateral (bottom plates). A few TrpV1-positive small fiber IENF are also seen (G, white arrows). Mag bar = 50 µm for all images. IENF, intraepidermal nerve fibers; PHN, postherpetic neuralgia; TrpV1, transient receptor potential vanilloid 1.

    Techniques Used: Biomarker Discovery, Immunolabeling, Labeling

    Keratinocyte biomarker immunolabeling average pixel intensity (API) in contralateral (black) and ipsilateral (grey) biopsies from the total PHN patient cohort. Asterisks indicate a significant ( P < 0.05) within-patient difference between the contralateral (nonpain) and ipsilateral (pain) biopsy labeling. PHN, postherpetic neuralgia.
    Figure Legend Snippet: Keratinocyte biomarker immunolabeling average pixel intensity (API) in contralateral (black) and ipsilateral (grey) biopsies from the total PHN patient cohort. Asterisks indicate a significant ( P < 0.05) within-patient difference between the contralateral (nonpain) and ipsilateral (pain) biopsy labeling. PHN, postherpetic neuralgia.

    Techniques Used: Biomarker Discovery, Immunolabeling, Labeling

    Keratinocyte biomarker API % difference of ipsilateral (pain) from contralateral (nonpain). Filled circles represent significant difference. The data show that for each of the biomarkers evaluated, a significant difference was seen in both directions among the total PHN cohort (n = 20). These data demonstrate the differential keratinocyte labeling for each biomarker, emphasizes the existence of patient subgroups within the enriched cohort, and highlights the potential for individualized topical treatment strategies based from skin biopsy analysis. API, average pixel intensity; PHN, postherpetic neuralgia.
    Figure Legend Snippet: Keratinocyte biomarker API % difference of ipsilateral (pain) from contralateral (nonpain). Filled circles represent significant difference. The data show that for each of the biomarkers evaluated, a significant difference was seen in both directions among the total PHN cohort (n = 20). These data demonstrate the differential keratinocyte labeling for each biomarker, emphasizes the existence of patient subgroups within the enriched cohort, and highlights the potential for individualized topical treatment strategies based from skin biopsy analysis. API, average pixel intensity; PHN, postherpetic neuralgia.

    Techniques Used: Biomarker Discovery, Labeling

    Individual patient biomarker response codes were ordered to demonstrate the differential labeling among individual patients of the enriched PHN cohort. Based from the observed tissue biomarker expression patterns, potential individualized topical treatment regimen with appropriate effective compounds can be rationally advised. PHN, postherpetic neuralgia.
    Figure Legend Snippet: Individual patient biomarker response codes were ordered to demonstrate the differential labeling among individual patients of the enriched PHN cohort. Based from the observed tissue biomarker expression patterns, potential individualized topical treatment regimen with appropriate effective compounds can be rationally advised. PHN, postherpetic neuralgia.

    Techniques Used: Biomarker Discovery, Labeling, Expressing



    Similar Products

    phn human research tissue  (Teva)
    90
    Teva phn human research tissue
    Keratinocyte biomarker immunolabeling examples demonstrate the discreet variability among individual patients of the innervation pathology-matched <t>PHN</t> cohort. For every biomarker (A–I), at least one individual patient within the total cohort had significantly less ipsilateral labeling than contralateral (top plates), and at least one individual patient within the total cohort also had significantly more ipsilateral labeling than contralateral (bottom plates). A few TrpV1-positive small fiber IENF are also seen (G, white arrows). Mag bar = 50 µm for all images. IENF, intraepidermal nerve fibers; PHN, postherpetic neuralgia; TrpV1, transient receptor potential vanilloid 1.
    Phn Human Research Tissue, supplied by Teva, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phn human research tissue/product/Teva
    Average 90 stars, based on 1 article reviews
    phn human research tissue - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Keratinocyte biomarker immunolabeling examples demonstrate the discreet variability among individual patients of the innervation pathology-matched PHN cohort. For every biomarker (A–I), at least one individual patient within the total cohort had significantly less ipsilateral labeling than contralateral (top plates), and at least one individual patient within the total cohort also had significantly more ipsilateral labeling than contralateral (bottom plates). A few TrpV1-positive small fiber IENF are also seen (G, white arrows). Mag bar = 50 µm for all images. IENF, intraepidermal nerve fibers; PHN, postherpetic neuralgia; TrpV1, transient receptor potential vanilloid 1.

    Journal: Pain Reports

    Article Title: Cutaneous targets for topical pain medications in patients with neuropathic pain: individual differential expression of biomarkers supports the need for personalized medicine

    doi: 10.1097/PR9.0000000000001121

    Figure Lengend Snippet: Keratinocyte biomarker immunolabeling examples demonstrate the discreet variability among individual patients of the innervation pathology-matched PHN cohort. For every biomarker (A–I), at least one individual patient within the total cohort had significantly less ipsilateral labeling than contralateral (top plates), and at least one individual patient within the total cohort also had significantly more ipsilateral labeling than contralateral (bottom plates). A few TrpV1-positive small fiber IENF are also seen (G, white arrows). Mag bar = 50 µm for all images. IENF, intraepidermal nerve fibers; PHN, postherpetic neuralgia; TrpV1, transient receptor potential vanilloid 1.

    Article Snippet: Deidentified PHN human research tissue for this study was collected before any drug treatments from an unrelated clinical study ( ClinTrials.gov NCT02365636/TEVA Pharmaceuticals) where each subject provided a contralateral and ipsilateral biopsy from the same thoracic dermatome.

    Techniques: Biomarker Discovery, Immunolabeling, Labeling

    Keratinocyte biomarker immunolabeling average pixel intensity (API) in contralateral (black) and ipsilateral (grey) biopsies from the total PHN patient cohort. Asterisks indicate a significant ( P < 0.05) within-patient difference between the contralateral (nonpain) and ipsilateral (pain) biopsy labeling. PHN, postherpetic neuralgia.

    Journal: Pain Reports

    Article Title: Cutaneous targets for topical pain medications in patients with neuropathic pain: individual differential expression of biomarkers supports the need for personalized medicine

    doi: 10.1097/PR9.0000000000001121

    Figure Lengend Snippet: Keratinocyte biomarker immunolabeling average pixel intensity (API) in contralateral (black) and ipsilateral (grey) biopsies from the total PHN patient cohort. Asterisks indicate a significant ( P < 0.05) within-patient difference between the contralateral (nonpain) and ipsilateral (pain) biopsy labeling. PHN, postherpetic neuralgia.

    Article Snippet: Deidentified PHN human research tissue for this study was collected before any drug treatments from an unrelated clinical study ( ClinTrials.gov NCT02365636/TEVA Pharmaceuticals) where each subject provided a contralateral and ipsilateral biopsy from the same thoracic dermatome.

    Techniques: Biomarker Discovery, Immunolabeling, Labeling

    Keratinocyte biomarker API % difference of ipsilateral (pain) from contralateral (nonpain). Filled circles represent significant difference. The data show that for each of the biomarkers evaluated, a significant difference was seen in both directions among the total PHN cohort (n = 20). These data demonstrate the differential keratinocyte labeling for each biomarker, emphasizes the existence of patient subgroups within the enriched cohort, and highlights the potential for individualized topical treatment strategies based from skin biopsy analysis. API, average pixel intensity; PHN, postherpetic neuralgia.

    Journal: Pain Reports

    Article Title: Cutaneous targets for topical pain medications in patients with neuropathic pain: individual differential expression of biomarkers supports the need for personalized medicine

    doi: 10.1097/PR9.0000000000001121

    Figure Lengend Snippet: Keratinocyte biomarker API % difference of ipsilateral (pain) from contralateral (nonpain). Filled circles represent significant difference. The data show that for each of the biomarkers evaluated, a significant difference was seen in both directions among the total PHN cohort (n = 20). These data demonstrate the differential keratinocyte labeling for each biomarker, emphasizes the existence of patient subgroups within the enriched cohort, and highlights the potential for individualized topical treatment strategies based from skin biopsy analysis. API, average pixel intensity; PHN, postherpetic neuralgia.

    Article Snippet: Deidentified PHN human research tissue for this study was collected before any drug treatments from an unrelated clinical study ( ClinTrials.gov NCT02365636/TEVA Pharmaceuticals) where each subject provided a contralateral and ipsilateral biopsy from the same thoracic dermatome.

    Techniques: Biomarker Discovery, Labeling

    Individual patient biomarker response codes were ordered to demonstrate the differential labeling among individual patients of the enriched PHN cohort. Based from the observed tissue biomarker expression patterns, potential individualized topical treatment regimen with appropriate effective compounds can be rationally advised. PHN, postherpetic neuralgia.

    Journal: Pain Reports

    Article Title: Cutaneous targets for topical pain medications in patients with neuropathic pain: individual differential expression of biomarkers supports the need for personalized medicine

    doi: 10.1097/PR9.0000000000001121

    Figure Lengend Snippet: Individual patient biomarker response codes were ordered to demonstrate the differential labeling among individual patients of the enriched PHN cohort. Based from the observed tissue biomarker expression patterns, potential individualized topical treatment regimen with appropriate effective compounds can be rationally advised. PHN, postherpetic neuralgia.

    Article Snippet: Deidentified PHN human research tissue for this study was collected before any drug treatments from an unrelated clinical study ( ClinTrials.gov NCT02365636/TEVA Pharmaceuticals) where each subject provided a contralateral and ipsilateral biopsy from the same thoracic dermatome.

    Techniques: Biomarker Discovery, Labeling, Expressing